TA-ERT — NDA/BLA submission
Q4 2026
Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026Source filing
SPRB biotech catalysts & pipeline
SPRUCE BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
tralesinidase alfa ("TA-ERT") — NDA/BLA submission
Q4 2026
We anticipate submitting a biologics license application of TA-ERT for the treatment of Sanfilippo Syndrome Type B in the fourth quarter of 2026.Source filing